Barclays’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.4M Sell
2,812,010
-2,726,991
-49% -$12.7M ﹤0.01% 1384
2025
Q4
$30.5M Buy
5,539,001
+390,889
+8% +$1.9M 0.01% 1016
2025
Q3
$16.8M Buy
5,148,112
+4,697,611
+1,043% +$13.3M ﹤0.01% 1327
2025
Q2
$1.04M Sell
450,501
-258,465
-36% -$562K ﹤0.01% 3312
2025
Q1
$985K Buy
708,966
+373,728
+111% +$625K ﹤0.01% 3118
2024
Q4
$587K Buy
335,238
+87,958
+36% +$182K ﹤0.01% 3727
2024
Q3
$512K Buy
247,280
+193,046
+356% +$424K ﹤0.01% 3761
2024
Q2
$117K Buy
+54,234
New +$158K ﹤0.01% 3830
2023
Q1
Sell
-44,013
Closed -$96.8K 5355
2022
Q4
$96.8K Sell
44,013
-3,866
-8% -$7.83K ﹤0.01% 4244
2022
Q3
$97K Hold
47,879
﹤0.01% 3553
2022
Q2
$184K Buy
47,879
+3,492
+8% +$13.9K ﹤0.01% 3479
2022
Q1
$273K Buy
+44,387
New +$332K ﹤0.01% 3248

Other funds holding TSHA